Insulin glulisine (Apidra)

Insulin glulisine is Sanofi's rapid-acting mealtime analog, sold as Apidra. Like every rapid analog it is the body's own insulin with two amino-acid swaps — here lysine and glutamic acid replace asparagine and lysine on the insulin B chain — that discourage the molecules from clumping so they absorb faster after a subcutaneous injection.¹ Its one formulation quirk is that it carries no added zinc: where aspart and lispro rely on zinc to form orderly six-molecule clusters in the vial, glulisine stays largely as single molecules and pairs, so it is ready to be absorbed the moment it is injected.¹

In practice this buys only a sliver of speed. Glulisine starts working in roughly 15 minutes, peaks at about an hour, and is largely gone in around 4 hours.² On the official label, its blood level peaks near 60 minutes after injection versus about 120 minutes for older "regular" human insulin, and its terminal half-life is about 42 minutes.³ Head-to-head against insulin lispro it shows slightly higher, slightly earlier insulin levels in the first half-hour after a meal, but the overall glucose control is equivalent and the difference is modest.⁴ We therefore rank it at the front of the standard rapid analogs, not among the newer ultra-rapid formulations (Fiasp, Lyumjev) that were engineered specifically to beat this curve — and far from a healthy pancreas.

Absorption is reassuringly consistent: within-person variability is low and, helpfully, holds steady across body weights and ethnic groups, since the zinc-free formulation does not depend on subcutaneous fat to disperse.¹ It can be dosed flexibly — within 15 minutes before a meal or up to 20 minutes after starting one — which helps with unpredictable appetites, especially in children.³

Delivery is the one place glulisine lags its peers. It is approved for injection by pen or syringe, for insulin-pump use, and (under medical supervision) intravenously.³ But in pumps it is the most fragile of the three classic rapid analogs: it is more prone to forming fibrils and inactive protein clumps, and one comparative analysis reported markedly higher infusion-set occlusion rates (about 41%, versus roughly 9% for aspart and 16% for lispro).⁵ A systematic review reached the same direction more cautiously — broadly similar stability, but a real signal that glulisine precipitates and occludes more readily under pump conditions.⁶ That makes it a strong pen insulin and a second-choice pump insulin.

Glulisine was approved by the FDA in 2004 (down to age 4) and by the EMA the same year (down to age 6), and is marketed across the US, EU, UK, Canada and Australia.³⁷ It has long been the least-prescribed of the three rapid analogs, with a smaller market share than aspart or lispro. On cost, Sanofi sharply cut Apidra's US list price effective January 2024 and now caps out-of-pocket cost for many patients, making it notably more affordable; there is not yet an approved biosimilar of glulisine.⁸

What's coming for glulisine specifically is mostly less, not more: with the patent era over, the realistic near-term change is price — potential biosimilar entry that would lower cost — rather than a faster reformulation. The speed frontier in mealtime insulin is being pushed by the ultra-rapid analogs and by experimental concentration-jump and warming approaches, none of which are built on glulisine. For most people it remains a dependable, now-cheaper mealtime pen insulin whose ceiling is the same subcutaneous-absorption physics that limits the whole class.

References

1. Becker RHA, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clinical Pharmacokinetics (2008). https://pubmed.ncbi.nlm.nih.gov/18076215/ ↩ ↩² ↩³

2. Garg SK, Ellis SL, Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opinion on Pharmacotherapy (2005). https://pubmed.ncbi.nlm.nih.gov/15934890/ ↩

3. APIDRA (insulin glulisine) injection — prescribing information. DailyMed / U.S. FDA (2022). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7af6a7a-8046-4fb4-9979-4ec4230b23aa ↩ ↩² ↩³ ↩⁴

4. Luzio S, Peter R, Dunseath GJ, Mustafa L, Owens DR. A comparison of preprandial insulin glulisine versus insulin lispro over a 12-h period. Diabetes Research and Clinical Practice (2007). https://doi.org/10.1016/j.diabres.2007.11.013 ↩

5. Bode BW. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of aspart, lispro and glulisine. Endocrine Practice (2011). https://pubmed.ncbi.nlm.nih.gov/21134878/ ↩

6. Kerr D, Wizemann E, Senstius J, Zacho M, Ampudia-Blasco FJ. Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review. Journal of Diabetes Science and Technology (2013). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876338/ ↩

7. Apidra (insulin glulisine) — European Public Assessment Report. European Medicines Agency (2004). https://www.ema.europa.eu/en/medicines/human/EPAR/apidra ↩

8. Sanofi announces insulin price cuts, $35 monthly cap for people with commercial insurance. Healio (2023). https://www.healio.com/news/endocrinology/20230317/sanofi-announces-insulin-price-cuts-35-monthly-cap-for-people-with-commercial-insurance ↩